Lv57
960 积分 2026-06-16 加入
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
5小时前
待确认
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
5小时前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
1天前
待确认
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
11天前
已完结
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
1个月前
已完结
Optimal two-stage designs for phase II clinical trials
1个月前
已完结
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
1个月前
已完结
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
1个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
1个月前
已完结
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
1个月前
已完结
皖公网安备34019202002308
